论文部分内容阅读
最近几年,由于实施了大规模的供者筛选计划和生产制备工艺的改进,已使因血液制品传播病毒性疾病的危险性明显地减少.尤其在美国,已获准生产的静脉注射免疫球蛋白(IVIG)制剂已赢得了安全制品的声誉.固然,IVIG 能排除人免疫缺陷病毒(HIV)感染,但是否也能排除非甲非乙型肝炎NANBH)的传播,尚难以确定.倘若可能的话,相信在IVIG 中NANBH 安全性的界限极为狭窄。事实上,有好几份报告已表明,有些实验批的IVIG 的输注与NANBH 的发生有关.为此,本文为了评估
In recent years, due to the implementation of large-scale donor screening programs and manufacturing processes improved, the risk of viral diseases caused by blood products has been significantly reduced.Especially in the United States, has been approved for the production of intravenous immunoglobulin (IVIG) has won the reputation for safe products, although it is difficult to determine if IVIG can rule out human immunodeficiency virus (HIV) infection but can also rule out the spread of non-A, non-B hepatitis NANBH.) If possible, It is believed that the boundaries of NANBH security in IVIG are extremely narrow. In fact, several reports have shown that infusion of IVIG in some experimental batches has been linked to the development of NANBH. To do this,